Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiniksa Pharmaceuticals International, plc filings document regulatory disclosures for a Nasdaq-listed biopharmaceutical company incorporated in England and Wales. Form 8-K reports cover operating results and financial condition, ARCALYST portfolio execution, investor presentations, and executive appointments or consulting arrangements.
Proxy materials cover annual meeting matters, director elections, executive compensation, shareholder voting procedures, and board governance. The filing record also identifies the company’s Class A ordinary shares, Nasdaq Global Select Market listing, and recurring disclosures tied to its commercial ARCALYST franchise and cardiovascular-focused development portfolio.
Kiniksa Pharmaceuticals (KNSA) Form 4 — transactions by Eben Tessari. The filing shows transactions on 09/15/2025 executed under a 10b5-1 plan established April 29, 2024. Tessari acquired 6,500 Class A ordinary shares by exercise of options at an $8.83 exercise price and reported ownership of 6,500 underlying shares from that option. On the same date Tessari sold 16,044 Class A shares at a weighted average price of $36.45 and sold 356 Class A shares at a weighted average price of $37. After these transactions reported beneficial ownership counts include 50,952, 34,908, and 34,552 shares respectively. The option involved is described as fully vested and exercisable.
Tessari Eben, Chief Operating Officer and director of Kiniksa Pharmaceuticals International, plc (KNSA), reported exercises of vested share options and subsequent sales on September 4 and 5, 2025 under a 10b5-1 plan. The reporting person exercised a total of 98,660 share options at exercise prices of $15.50 and $15.52, resulting in the acquisition of 98,660 Class A Ordinary Shares. That same week the reporting person sold 98,660 Class A Ordinary Shares in multiple brokered trades at weighted-average prices of about $35.52 and $35.66. After these transactions the reporting person beneficially owned 44,452 Class A Ordinary Shares. The 10b5-1 plan was executed on April 29, 2024, and the Form 4 was signed by an attorney-in-fact on September 8, 2025.
Kiniksa Pharmaceuticals (KNSA) insider sale: Ross Moat, Chief Corporate & Commercial Officer and director, reported a disposition of 3,523 Class A ordinary shares on 09/04/2025 at a price of $35.31 per share. Following the sale, Mr. Moat beneficially owned 9,415 Class A ordinary shares directly. The filing notes the sale was executed pursuant to a 10b5-1 trading plan adopted on November 13, 2024. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 notice reports a proposed sale of 13,389 Class A ordinary shares through Charles Schwab & Co., Inc. on 09/05/2025, with an aggregate market value of $477,497.00. The shares were acquired the same day by employee stock option exercise and the payment method is listed as broker payment for cashless exercise. The filing lists multiple prior sales by the same seller, Eben Tessari, between 06/09/2025 and 09/04/2025, including several larger transactions reported on 06/11/2025, 08/05/2025 and 09/04/2025. Outstanding shares are shown as 43,472,928.
Kiniksa Pharmaceuticals International, plc (KNSA) filed a Form 144 notifying a proposed sale of 85,271 Class A ordinary shares through Charles Schwab & Co., Inc. with an aggregate market value of $3,028,740, approximately to be sold on 09/04/2025 on NASDAQ. The shares were acquired the same day via an employee stock option exercise and were settled by a broker payment for a cashless exercise.
The filing also lists insider sales over the past three months by Eben Tessari totaling 381,932 shares across multiple dates with combined gross proceeds of $7,482,197.
Kiniksa Pharmaceuticals International, plc (KNSA) reported a Form 144 notice for a proposed sale of 3,523 Class A ordinary shares through Charles Schwab & Co., with an aggregate market value of $124,397. The filing shows the shares were acquired by restricted stock lapse as equity compensation on 09/01/2025 (3,010 shares) and 09/02/2025 (513 shares). The company’s total outstanding Class A shares are listed as 43,472,928, and the sale is scheduled approximately for 09/04/2025. The notice contains the standard attestations about absence of undisclosed material information and compliance with Rule 144 and Rule 10b5-1 disclosures.
Kiniksa Pharmaceuticals (KNSA) Form 4 — Tessari Eben, Chief Operating Officer. The filing shows multiple equity awards and transactions between September 1–3, 2025. RSUs were granted/recorded totaling 9,828 RSUs on 09/01/2025 and additional RSUs from prior grants are reflected; each RSU converts to one Class A ordinary share. New stock options were granted on 09/01/2025 for 39,364 shares at a $33.49 exercise price and earlier vested options and RSUs remain outstanding. The reporting person sold 15,091 Class A shares on 09/03/2025 at a weighted average price of $35.50 and recorded additional small open-market sales on 09/01–09/02 at $33.49 and $34.28. Post-transactions beneficial ownership totals are reported in the range of 43,438 to 59,543 Class A shares depending on line items.
Kiniksa Pharmaceuticals International, plc (KNSA) Form 144 reports an intended sale of 15,091 Class A ordinary shares through Charles Schwab & Co., Inc. for an aggregate market value of $535,778, to be traded on NASDAQ approximately on 09/03/2025. The shares were acquired the same day by an employee stock option exercise and the transaction indicates a broker payment for a cashless exercise.
The filing also discloses insider sales by Eben Tessari during the prior three months totaling 261,881 shares for aggregate gross proceeds of $8,341,479 across seven transactions between 06/09/2025 and 08/18/2025. The filing provides specific trade dates, amounts, and proceeds but does not include additional context or reasons for the sales.
Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions from September 1–3, 2025. The filings show a series of restricted share unit (RSU) grants, option exercises and open-market trades executed pursuant to a 10b5-1 plan. On September 3, 2025 the reporting person exercised a share option for 11,000 Class A Ordinary Shares at an exercise price of $17.92 and sold 11,000 shares in the market at a weighted average price of $34.84. Several RSU awards and stock options were granted or recognized on September 1–2, 2025 with various vesting schedules; one option grant has an exercise price of $33.49 and expires August 31, 2035. Following the reported transactions the reporting person beneficially owned 38,011 Class A Ordinary Shares.
Ross Moat, Chief Corporate & Commercial Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions on September 1-2, 2025. The filing shows grant and acquisition of restricted share units (RSUs) and a stock option, and reported dispositions of Class A ordinary shares at prices of $33.49 and $34.28. The derivative section shows an option for 39,364 Class A shares and RSUs representing 9,828 Class A shares, each with specified multi-year vesting schedules. Following the reported transactions, the Form 4 lists beneficial ownership figures for Class A ordinary shares in the range shown, with the last reported post-transaction direct ownership of 12,938 Class A ordinary shares. The filing includes detailed vesting terms: option vesting begins September 1, 2025, and RSUs vest over four-year schedules with 25% annual vesting.